JP2022529782A5 - - Google Patents
Info
- Publication number
- JP2022529782A5 JP2022529782A5 JP2021562000A JP2021562000A JP2022529782A5 JP 2022529782 A5 JP2022529782 A5 JP 2022529782A5 JP 2021562000 A JP2021562000 A JP 2021562000A JP 2021562000 A JP2021562000 A JP 2021562000A JP 2022529782 A5 JP2022529782 A5 JP 2022529782A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- isolated nucleic
- vector
- raav
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962836493P | 2019-04-19 | 2019-04-19 | |
| US62/836,493 | 2019-04-19 | ||
| PCT/US2020/028504 WO2020214809A2 (en) | 2019-04-19 | 2020-04-16 | Gene therapies for stargardt disease (abca4) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022529782A JP2022529782A (ja) | 2022-06-24 |
| JP2022529782A5 true JP2022529782A5 (cg-RX-API-DMAC7.html) | 2023-04-25 |
Family
ID=72838359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562000A Ceased JP2022529782A (ja) | 2019-04-19 | 2020-04-16 | シュタルガルト病(abca4)の遺伝子治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12516097B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3955973A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022529782A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114126665B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020257392A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3137135A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020214809A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12516097B2 (en) | 2019-04-19 | 2026-01-06 | University Of Massachusetts | Gene therapies for Stargardt disease (ABCA4) |
| WO2021055760A1 (en) | 2019-09-18 | 2021-03-25 | Intergalactic Therapeutics, Inc. | Synthetic dna vectors and methods of use |
| MX2023001109A (es) | 2020-07-27 | 2023-04-24 | Anjarium Biosciences Ag | Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas. |
| EP4281053A4 (en) * | 2021-01-22 | 2024-12-25 | Cornell University | COMPOSITIONS AND METHODS FOR IDENTIFYING COMPOUNDS THAT PROTECT AGAINST LIPOFUSCIN CYTOTOXICITY |
| WO2022198025A2 (en) * | 2021-03-19 | 2022-09-22 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing pfic therapeutics |
| EP4330409A4 (en) | 2021-04-26 | 2025-04-09 | University of Massachusetts | GENE THERAPIES FOR STARGARDT'S DISEASE (ABCA4) |
| US20240425877A1 (en) * | 2021-05-07 | 2024-12-26 | Ucl Business Ltd | Abca4 genome editing |
| CN115074369B (zh) * | 2022-06-24 | 2023-10-20 | 成都金唯科生物科技有限公司 | 表达全长abca4基因的腺相关病毒载体及应用 |
| CN116217695A (zh) * | 2022-11-21 | 2023-06-06 | 良培基因生物科技(武汉)有限公司 | 多肽、多肽组合、核酸、核酸组合、检测剂及应用 |
| CN116042635A (zh) * | 2022-11-21 | 2023-05-02 | 良培基因生物科技(武汉)有限公司 | 一种分离的编码abca4突变体的核酸、检测剂及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| US7943374B2 (en) * | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| US20090214478A1 (en) | 2008-02-21 | 2009-08-27 | Alberto Auricchio | Method of treating ocular diseases by gene therapy |
| US20110172107A1 (en) | 2008-04-30 | 2011-07-14 | Fox Chase Cancer Center | Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby |
| ES2822551T3 (es) | 2014-03-17 | 2021-05-04 | Adverum Biotechnologies Inc | Composiciones y métodos para la expresión génica mejorada en células de los conos |
| AU2016355343C1 (en) | 2015-11-19 | 2024-10-03 | Lloyd G. Mitchell | Compositions and methods for correction of heritable ocular disease |
| WO2018109011A1 (en) | 2016-12-13 | 2018-06-21 | Stichting Katholieke Universiteit | Antisense oligonucleotides for the treatment of stargardt disease |
| CA3054735A1 (en) | 2017-02-27 | 2018-08-30 | Case Western Reserve University | Visual cycle modulators |
| US12516097B2 (en) | 2019-04-19 | 2026-01-06 | University Of Massachusetts | Gene therapies for Stargardt disease (ABCA4) |
| EP4330409A4 (en) | 2021-04-26 | 2025-04-09 | University of Massachusetts | GENE THERAPIES FOR STARGARDT'S DISEASE (ABCA4) |
-
2020
- 2020-04-16 US US17/604,556 patent/US12516097B2/en active Active
- 2020-04-16 AU AU2020257392A patent/AU2020257392A1/en not_active Abandoned
- 2020-04-16 EP EP20791568.7A patent/EP3955973A4/en active Pending
- 2020-04-16 JP JP2021562000A patent/JP2022529782A/ja not_active Ceased
- 2020-04-16 CA CA3137135A patent/CA3137135A1/en active Pending
- 2020-04-16 WO PCT/US2020/028504 patent/WO2020214809A2/en not_active Ceased
- 2020-04-16 CN CN202080044221.2A patent/CN114126665B/zh active Active
-
2025
- 2025-10-02 US US19/347,786 patent/US20260022154A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7574508B2 (ja) | 血管系を通過する遺伝子移入の方法および組成物 | |
| CN106459932B (zh) | 高胆红素血症的治疗 | |
| US12589167B2 (en) | AAV gene therapy vector with podocyte-specific promoter | |
| TW201629225A (zh) | 第九因子基因療法 | |
| JP2023535956A5 (cg-RX-API-DMAC7.html) | ||
| JP2023088902A5 (cg-RX-API-DMAC7.html) | ||
| AU2021319065A1 (en) | Improved AAV-mediated X-linked retinoschisis therapies | |
| EP3472328A1 (en) | Dual overlapping adeno-associated viral vector system for expressing abc4a | |
| JP7702949B2 (ja) | ヒトmecp2遺伝子を発現するように設計されたトランスジーンカセット | |
| JP2020512822A5 (cg-RX-API-DMAC7.html) | ||
| CN111876432B (zh) | 一组肝靶向新型腺相关病毒的获得及其应用 | |
| JP2017529395A5 (cg-RX-API-DMAC7.html) | ||
| JP2022529782A (ja) | シュタルガルト病(abca4)の遺伝子治療 | |
| CN118546216A (zh) | 提高aav病毒视网膜穿透能力的衣壳蛋白突变体及其应用 | |
| JP2021534766A5 (cg-RX-API-DMAC7.html) | ||
| WO2025011566A1 (zh) | 一种用于过敏性疾病的基因治疗载体核酸构建体及其使用方法 | |
| JP2022552892A5 (cg-RX-API-DMAC7.html) | ||
| JP2023522883A (ja) | 神経学的障害を処置するための組成物および方法 | |
| AU2020212026B2 (en) | Highly efficient transduction and lateral spread in the retina by a novel AAV virus enhanced by rational design | |
| KR102855673B1 (ko) | 폐 세포 특이적 유전자 전달이 가능한 아데노부속바이러스 벡터 | |
| US20220389450A1 (en) | Vector system | |
| KR102855674B1 (ko) | 폐 기관지 특이적 유전자 전달이 가능한 아데노부속바이러스 벡터 | |
| EP4615492A1 (en) | Polynucleotide and vector | |
| CN112063625A (zh) | 编码arl2bp的核酸及其应用 | |
| HK40092158A (en) | A gene therapy vector nucleic acid construct for allergic diseases and method of using same |